NCT06815666 BAL Fluid Biomarkers in Sarcoma
| NCT ID | NCT06815666 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | University Health Network, Toronto |
| Condition | Soft Tissue Sarcoma (STS) |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2025-01-29 |
| Primary Completion | 2032-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 70 participants in total. It began in 2025-01-29 with a primary completion date of 2032-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years 2. Ability to understand and willingness to sign a written informed consent document 3. Diagnosed with soft tissue sarcoma 4. Undergoing resection of lung lesion as part of standard care Exclusion Criteria: 1\. History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ 2 years
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06815666 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Soft Tissue Sarcoma (STS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06815666 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06815666 currently recruiting?
Yes, NCT06815666 is actively recruiting participants. Contact the research team at david.shultz@uhn.ca for enrollment information.
Where is the NCT06815666 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT06815666 clinical trial?
NCT06815666 is sponsored by University Health Network, Toronto. The trial plans to enroll 70 participants.